

DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION

Use this check box to generate the required 483 statement on page 1 for medical device observations.

| | |
|--|---|
| DISTRICT ADDRESS AND PHONE NUMBER 4040 North Central Expressway, Suite 300 Dallas, TX 75204 (214) 253-5200 Fax: (214) 253-5314 ORAPharm2_responses@fda.hhs.gov | DATE(S) OF INSPECTION 11/18/2019-11/22/2019* |
| | FEI NUMBER 3004102002 |

NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED
 Jack R. Munn, Owner/Pharmacist-in-Charge

| | |
|---|---|
| FIRM NAME MPRX, Inc. dba Medical Park Pharmacy | STREET ADDRESS 8230 Elmbrook Dr Ste 600B |
|---|---|

| | |
|---|---|
| CITY, STATE, ZIP CODE, COUNTRY Dallas, TX 75247-4144 | TYPE ESTABLISHMENT INSPECTED Producer of Non-Sterile Drugs |
|---|---|

DURING AN INSPECTION OF YOUR FIRM I OBSERVED:

OBSERVATION 1

Your firm released drug product in which the strength differs from, or its purity or quality falls below, that which it purports or is represented to possess.

Specifically, during my review of your October 2019 Formula Worksheets, (b) (4) of (b) (4) lots of products were produced using at least one expired bulk drug substance/chemical including, but not limited to the following: Phenylephrine, Desonide, Dexamethasone, Liothyronine, Acesulfame Potassium, Gabapentin and Cyclobenzaprine.

OBSERVATION 2

Calibration of mechanical equipment is not performed daily or on a routine schedule designed to assure proper performance.

Specifically,


- a) You have not calibrated the scale used to weigh bulk drug substances/chemicals since you moved to this location.
- b) You stated, and I observed you do not verify the weighing of ingredients/components for each lot made.
- c) Formula Worksheets do not list ingredients and the quantity of each in the order of the manufacturing process.

OBSERVATION 3

You produced highly potent drugs without providing adequate to prevent cross-contamination.

Specifically, you do not document the cleaning of the (b) (4) hood and the hood used and non-dedicated equipment (i.e. (b) (4), etc.) to demonstrate control of cross contamination between highly potent drugs.

| | | | |
|--------------------------|--|--|-------------------------------|
| SEE REVERSE OF THIS PAGE | EMPLOYEE(S) SIGNATURE <i>Claire M. Minden</i> | EMPLOYEE(S) NAME AND TITLE (Print or Type) Claire M. Minden, Investigator | DATE ISSUED 11/22/2019 |
| | Digitally signed by Claire M. Minden -S DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, 0.9.2342.19200300.100.1.1=1300178102, cn=Claire M. Minden -S Date: 2019.11.22 13:34:56 -06'00' | | |

| DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG | | | |
|---|--|---|---------------------------|
| DISTRICT OFFICE ADDRESS AND PHONE NUMBER 4040 North Central Expressway, Suite 300 Dallas, TX 75204 (214)253-5200 Fax:(214)253-5314 ORAPharm2_responses@fda.hhs.gov | | DATE(S) OF INSPECTION 11/18/2019-11/22/2019* | |
| | | FEI NUMBER 3004102002 | |
| NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED Jack R. Munn, Owner/Pharmacist-in-Charge | | | |
| FIRM NAME MPRX, Inc. dba Medical Park Pharmacy | | STREET ADDRESS 8230 Elmbrook Dr Ste 600B | |
| CITY, STATE, ZIP CODE, COUNTRY Dallas, TX 75247-4144 | | TYPE ESTABLISHMENT INSPECTED Producer of Non-Sterile Drugs | |
| <p>OBSERVATION 4 Vermin was observed in your production area.</p> <p>Specifically, on November 20, 2019, I observed an insect in the pharmacy area on the floor where compounding activities occur.</p> | | | |
| <p>*DATES OF INSPECTION 11/18/2019(Mon), 11/19/2019(Tue), 11/20/2019(Wed), 11/22/2019(Fri)</p> | | | |
| SEE REVERSE OF THIS PAGE | EMPLOYEE(S) SIGNATURE  | EMPLOYEE(S) NAME AND TITLE (<i>Print or Type</i>) Claire M. Minden, Investigator | DATE ISSUED 11/22/2019 |
| | <small>Digitally signed by Claire M. Minden -S DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, 0.9.2342.19200300.100.1.1=1300178102, cn=Claire M. Minden -S Date: 2019.11.22 13:35:47 -06'00'</small> | | |